中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 12
Dec.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(12): 2524-2530

Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma

DOI: 10.12449/JCH241225
  • a.

    Department of Hepatobiliary Diseases, The Third Affiliated Hospital of Navy Medical University，Shanghai 200438，China

  • b.

    National Center for Liver Cancer, The Third Affiliated Hospital of Navy Medical University，Shanghai 200438，China

Research funding:

National Major Scientific Instrument and Equipment Development Project (2012YQ220113)

  • Received Date: 2024-03-04
  • Accepted Date: 2024-05-09
  • Published Date: 2024-12-25
    Abstract
  • Hepatocellular carcinoma is the most common malignancy of the liver and poses serious health burdens on China and the whole world. However， most patients with hepatocellular carcinoma are already in the advanced stage at the time of diagnosis， with fewer opportunities for surgery and limited treatment options. In recent years， the advances in molecular targeted therapies have brought new hope for patients with advanced hepatocellular carcinoma. Among these therapies， lenvatinib is the second first-line drug after sorafenib approved by the US Food and Drug Administration for the treatment of advanced hepatocellular carcinoma， and it has attracted widespread attention for its powerful anti-tumor properties. However， the efficacy of lenvatinib is severely limited by its drug resistance. This article reviews the research advances in the molecular mechanisms of lenvatinib resistance in hepatocellular carcinoma and discusses possible ways to improve the efficacy of lenvatinib， so as to improve its efficacy.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    REHMAN O, JAFERI U, PADDA I, et al. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma[J]. Clin Exp Hepatol, 2021, 7( 3): 249- 257. DOI: 10.5114/ceh.2021.109312.
    [3]
    KUDO M, FINN RS, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [4]
    MATSUKI M, HOSHI T, YAMAMOTO Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models[J]. Cancer Med, 2018, 7( 6): 2641- 2653. DOI: 10.1002/cam4.1517.
    [5]
    OGASAWARA S, MIHARA Y, KONDO R, et al. Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo[J]. Anticancer Res, 2019, 39( 11): 5973- 5982. DOI: 10.21873/anticanres.13802.
    [6]
    JIN HJ, SHI YP, LV YY, et al. EGFR activation limits the response of liver cancer to lenvatinib[J]. Nature, 2021, 595( 7869): 730- 734. DOI: 10.1038/s41586-021-03741-7.
    [7]
    HE XP, HIKIBA Y, SUZUKI Y, et al. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells[J]. Sci Rep, 2022, 12( 1): 8007. DOI: 10.1038/s41598-022-12076-w.
    [8]
    WANG LN, YANG QX, ZHOU QY, et al. METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma[J]. Cancer Lett, 2023, 559: 216122. DOI: 10.1016/j.canlet.2023.216122.
    [9]
    HUANG ML, LONG JT, YAO ZJ, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma[J]. Cancer Res, 2023, 83( 1): 89- 102. DOI: 10.1158/0008-5472.CAN-22-0963.
    [10]
    ZHAO ZW, ZHANG DK, WU FZ, et al. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression[J]. J Cell Mol Med, 2021, 25( 1): 549- 560. DOI: 10.1111/jcmm.16108.
    [11]
    BYRON SA, CHEN HB, WORTMANN A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors[J]. Neoplasia, 2013, 15( 8): 975- 988. DOI: 10.1593/neo.121106.
    [12]
    ZHAO ZW, SONG JJ, ZHANG DK, et al. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib[J]. Life Sci, 2021, 264: 118642. DOI: 10.1016/j.lfs.2020.118642.
    [13]
    WANG JQ, WU ZX, YANG YQ, et al. ATP-binding cassette(ABC) transporters in cancer: A review of recent updates[J]. J Evid Based Med, 2021, 14( 3): 232- 256. DOI: 10.1111/jebm.12434.
    [14]
    SHUMAKER RC, ALURI J, FAN J, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults[J]. Clin Drug Investig, 2014, 34( 9): 651- 659. DOI: 10.1007/s40261-014-0217-y.
    [15]
    SHUMAKER R, ALURI J, FAN J, et al. Effects of ketoconazole on the pharmacokinetics of lenvatinib(E7080) in healthy participants[J]. Clin Pharmacol Drug Dev, 2015, 4( 2): 155- 160. DOI: 10.1002/cpdd.140.
    [16]
    SUN DW, LIU J, WANG YF, et al. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma[J]. Front Oncol, 2022, 12: 944537. DOI: 10.3389/fonc.2022.944537.
    [17]
    ONORATI AV, DYCZYNSKI M, OJHA R, et al. Targeting autophagy in cancer[J]. Cancer, 2018, 124( 16): 3307- 3318. DOI: 10.1002/cncr.31335.
    [18]
    HU FQ, SONG D, YAN YM, et al. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation[J]. Nat Commun, 2021, 12( 1): 3651. DOI: 10.1038/s41467-021-23923-1.
    [19]
    XU WP, LIU JP, FENG JF, et al. MiR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy[J]. Gut, 2020, 69( 7): 1309- 1321. DOI: 10.1136/gutjnl-2019-318830.
    [20]
    PAN JM, ZHANG M, DONG LQ, et al. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma[J]. Autophagy, 2023, 19( 4): 1184- 1198. DOI: 10.1080/15548627.2022.2117893.
    [21]
    ZHANG YX, ZHANG YJ, TAO HS, et al. Targeting LINC01607 sensitizes hepatocellular carcinoma to lenvatinib via suppressing mitophagy[J]. Cancer Lett, 2023, 576: 216405. DOI: 10.1016/j.canlet.2023.216405.
    [22]
    FERNÁNDEZ-PALANCA P, PAYO-SERAFÍN T, SAN-MIGUEL B, et al. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation[J]. Acta Pharmacol Sin, 2023, 44( 5): 1066- 1082. DOI: 10.1038/s41401-022-01021-2.
    [23]
    WANG BJ, TIAN T, KALLAND KH, et al. Targeting Wnt/β-catenin signaling for cancer immunotherapy[J]. Trends Pharmacol Sci, 2018, 39( 7): 648- 658. DOI: 10.1016/j.tips.2018.03.008.
    [24]
    RUSSELL JO, MONGA SP. Wnt/β-catenin signaling in liver development, homeostasis, and pathobiology[J]. Annu Rev Pathol, 2018, 13: 351- 378. DOI: 10.1146/annurev-pathol-020117-044010.
    [25]
    GUO YR, XU J, DU Q, et al. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma(HCC) through regulating β-catenin[J]. Transl Oncol, 2021, 14( 6): 101059. DOI: 10.1016/j.tranon.2021.101059.
    [26]
    WANG JH, YU HM, DONG W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways[J]. Gastroenterology, 2023, 164( 6): 990- 1005. DOI: 10.1053/j.gastro.2023.01.041.
    [27]
    LEUNG CON, YANG Y, LEUNG RWH, et al. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma[J]. Nat Commun, 2023, 14( 1): 6699. DOI: 10.1038/s41467-023-42360-w.
    [28]
    VENKATESH V, NATARAJ R, THANGARAJ GS, et al. Targeting Notch signalling pathway of cancer stem cells[J]. Stem Cell Investig, 2018, 5: 5. DOI: 10.21037/sci.2018.02.02.
    [29]
    TAKEBE N, MIELE L, HARRIS PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update[J]. Nat Rev Clin Oncol, 2015, 12( 8): 445- 464. DOI: 10.1038/nrclinonc.2015.61.
    [30]
    ZHANG XY, SU TH, WU YF, et al. N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression[J]. Cancer Res, 2024, 84( 6): 827- 840. DOI: 10.1158/0008-5472.CAN-23-1916.
    [31]
    FENG WQ, ZHANG HX, YU Q, et al. Study on the mechanism of Notch pathway mediates the role of lenvatinib-resistant hepatocellular carcinoma based on organoids[J]. Curr Mol Med, 2024. DOI: 10.2174/0115665240268201231213095302.[ Online ahead of print]
    [32]
    YANG SB, ZHOU ZH, LEI J, et al. TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC[J]. Biol Direct, 2023, 18( 1): 18. DOI: 10.1186/s13062-023-00376-8.
    [33]
    MOON H, RO SW. MAPK/ERK signaling pathway in hepatocellular carcinoma[J]. Cancers, 2021, 13( 12): 3026. DOI: 10.3390/cancers13123026.
    [34]
    HUANG SZ, MA ZY, ZHOU Q, et al. Genome-wide CRISPR/Cas9 library screening identified that DUSP4 deficiency induces lenvatinib resistance in hepatocellular carcinoma[J]. Int J Biol Sci, 2022, 18( 11): 4357- 4371. DOI: 10.7150/ijbs.69969.
    [35]
    CHEN HF, CHUANG HC, TAN TH. Regulation of dual-specificity phosphatase(DUSP) ubiquitination and protein stability[J]. Int J Mol Sci, 2019, 20( 11): 2668. DOI: 10.3390/ijms20112668.
    [36]
    LU YG, SHEN HM, HUANG WJ, et al. Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance[J]. Cell Death Discov, 2021, 7( 1): 359. DOI: 10.1038/s41420-021-00747-y.
    [37]
    MOOSAVI F, GIOVANNETTI E, SASO L, et al. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers[J]. Crit Rev Clin Lab Sci, 2019, 56( 8): 533- 566. DOI: 10.1080/10408363.2019.1653821.
    [38]
    FU RD, JIANG ST, LI JY, et al. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression[J]. Med Oncol, 2020, 37( 4): 24. DOI: 10.1007/s12032-020-01350-4.
    [39]
    XU X, JIANG WJ, HAN P, et al. MicroRNA-128-3p mediates lenvatinib resistance of hepatocellular carcinoma cells by downregulating c-met[J]. J Hepatocell Carcinoma, 2022, 9: 113- 126. DOI: 10.2147/JHC.S349369.
    [40]
    JIANG XJ, STOCKWELL BR, CONRAD M. Ferroptosis: Mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22( 4): 266- 282. DOI: 10.1038/s41580-020-00324-8.
    [41]
    ISEDA N, ITOH S, TOSHIDA K, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma[J]. Cancer Sci, 2022, 113( 7): 2272- 2287. DOI: 10.1111/cas.15378.
    [42]
    DUAN AQ, LI H, YU WL, et al. Long noncoding RNA XIST promotes resistance to lenvatinib in hepatocellular carcinoma cells via epigenetic inhibition of NOD2[J]. J Oncol, 2022, 2022: 4537343. DOI: 10.1155/2022/4537343.
    [43]
    WANG Y, TAN K, HU W, et al. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma[J]. Exp Cell Res, 2022, 420( 1): 113335. DOI: 10.1016/j.yexcr.2022.113335.
    [44]
    YU T, YU JJ, LU L, et al. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis[J]. Cell Oncol, 2021, 44( 4): 821- 834. DOI: 10.1007/s13402-021-00605-0.
    [45]
    ZHANG PF, SUN HX, WEN PH, et al. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma[J]. Mol Ther Nucleic Acids, 2022, 27: 293- 303. DOI: 10.1016/j.omtn.2021.12.001.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (89) PDF downloads(21) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return